Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation

Authors
Zilz, ND Olson, LJ McGregor, CG
Citation
Nd. Zilz et al., Treatment of post-transplant lymphoproliferative disorder with monoclonal CD20 antibody (rituximab) after heart transplantation, J HEART LUN, 20(7), 2001, pp. 770-772
Citations number
22
Categorie Soggetti
Cardiovascular & Respiratory Systems
Journal title
JOURNAL OF HEART AND LUNG TRANSPLANTATION
ISSN journal
10532498 → ACNP
Volume
20
Issue
7
Year of publication
2001
Pages
770 - 772
Database
ISI
SICI code
1053-2498(200107)20:7<770:TOPLDW>2.0.ZU;2-A
Abstract
Post-transplant lymphoproliferative disorder (PTLD) is a frequent and often fatal complication of organ transplantation. It most often results from an Epstein-Barr virus (EBV)-transformed B-cell clone, which expresses B-cell surface markers such as CD20. We describe a case of a heart transplant reci pient who EBV seroconverted posttransplant and subsequently developed subcu taneous and lymphatic B-cell lymphoma, successfully treated with CD20 antib ody (rituximab). The patient has been in remission during 10 months of clin ical follow-up.